Reformation hits pricing day, but retail IPO access is still unverified (2026)

Today's spotlight: Reformation reaches pricing day, but access is still unverified

Status: Expected to price Wednesday night, July 29, and trade Thursday, July 30. These are calendar estimates, not a final price or a confirmed broker allocation. 1 Ticker: REF Exchange: NYSE Price range: $15.00-$17.00 Shares offered: 14,062,500, including 4,583,679 shares sold by existing stockholders Minimum buy-in: No verified IPO allocation Broker access: No public allocation was verified through Robinhood, Fidelity, Schwab, E*TRADE, or Webull

Reformation is a direct-to-consumer women's fashion brand that sells apparel and accessories through online, retail, outlet, concession, and wholesale channels. Its 2025 net revenue was $507.1 million, up from a business that the filing says compounded revenue at 34% a year from 2015 through 2025. The company also reports 20 straight quarters of double-digit net-revenue growth. 2

The number that matters for the growth story is $507.1 million of 2025 revenue. The number that matters for the offering structure is 4.58 million. Those shares are being sold by existing holders, and Reformation says it will receive no proceeds from that block. The IPO is therefore a mix of new capital and shareholder selling, not a clean bet that every dollar raised goes into expansion. 2

The main risk is that fashion demand can move faster than a supply chain or a brand can adjust. The filing points to customer-retention, trend, tariff, supply-chain, and debt risks. Its first-quarter 2026 net loss was $12.1 million even though adjusted EBITDA was $15.9 million, so the headline growth does not remove the need to watch cash generation and execution. 2

For a retail investor, the practical read is short: REF may become a normal NYSE trading symbol after pricing, but that is different from receiving IPO shares. The $15-$17 range is an estimate until the company and underwriters publish a final price.

Actionable now

No open U.S. retail IPO allocation was verified in the 48-hour window covering Wednesday, July 29 through Friday morning, July 31. Public IPO calendars confirm deal terms and expected trading dates, but they do not prove that a customer can submit an allocation request through a mainstream broker. 3

Ticker	Price range	Minimum buy-in	Deadline	Verified brokers	Status
None verified	Not available	Not available	No verified open window	None publicly verified	Watch only

A listing-day purchase, including REF after its opening, would be secondary-market trading. It is not an IPO subscription.

Market pulse

Reformation has a measurable retail-facing audience. Its filing reports about 4 million social-media followers, 3 million email subscribers, and 70 stores as of June 27, 2026. That gives the brand a built-in customer funnel, but it does not tell us how many followers will become shareholders. 2
Jersey Mike's is the largest recognizable U.S. deal in the immediate queue. Its proposed offering is 43.5 million shares at $21-$25, or about $1.0 billion at the midpoint, with expected NYSE trading on July 30. Its public terms page does not identify a mainstream retail allocation channel. 4
Apnimed brings a near-term regulatory catalyst. The July 27 S-1/A describes a 10-million-share Nasdaq offering at $14-$16. Its sleep-apnea drug candidate Oxnimbi has an FDA NDA accepted in July, with a PDUFA target date of February 28, 2027. The same filing says the company has continued-loss and single-product risks. 5

HK desk

No verified Hong Kong public subscription was found still open today or closing within the next two days. Zhongji InnoLight's public offer closed on July 27; the company set its final H-share price at HK$980 and expects to list on July 30. The accessible public-offer page lists HK$1,010 as the earlier offer price and confirms the July 27 closing date, so do not treat HK$1,010 as the final price. 6 7

The final-price report says the base offering was 54.5 million H shares and that the Hong Kong public offer drew more than 13 times demand, with 33 cornerstone investors. Those are demand and pricing signals after the application window, not a live order opportunity. 6

HK offer	Offer status	Final price	Board lot	Deadline	Listing
Zhongji InnoLight (3308)	Closed	HK$980	Not re-verified in the accessible current page	July 27	July 30 6
None else verified	No open offer confirmed	Not available	Not available	None verified	Not available

HKEX's public pages did not expose a complete live subscription table in this run. The HK desk is therefore a verified no-action list, not a guarantee that every broker or exchange page showed no other offer.

On the radar

Name	Expected pricing	Expected listing	Terms	Why watch
Jersey Mike's (JMKE)	July 29	July 30	$21-$25; 43.5 million shares; about $1.0 billion	Large consumer brand, with a high share count and no verified mainstream retail allocation. 4
Apnimed (APMD)	July 30	July 31	$14-$16; 10 million shares; $150 million calendar size	FDA review of Oxnimbi is the central catalyst; the filing also flags financing, approval, and single-product risks. 5

July 29 is a normal NYSE trading day, not a scheduled holiday. The useful check today is whether a final price and a real broker allocation appear. Until then, REF, JMKE, and APMD are watchlist events, not verified subscription opportunities. This is market information, not investment advice. 8

Sources and coverage note

The U.S. terms above come from SEC filings and public IPO calendar pages. Hong Kong coverage uses an accessible exchange-related report and Phillip's public IPO page because the HKEX pages returned an incomplete or non-readable live table; treat the HK desk as lower-coverage than the U.S. section.

Reformation hits pricing day, but retail IPO access is still unverified